Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Sci Rep. 2024 Feb 2;14(1):2782. doi: 10.1038/s41598-024-53265-z.
Bladder cancer (BC) is a crisis to human health. It is necessary to understand the molecular mechanisms of the development and progression of BC to determine treatment options. Publicly available expression data were obtained from TCGA and GEO databases to spot differentially expressed genes (DEGs) between cancer and normal bladder tissues. Weighted co-expression networks were constructed, and Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Associations in hub genes, immune infiltration, and immune therapy were evaluated separately. Protein-protein interaction (PPI) networks for the genes identified in the normal and tumor groups were launched. 3461 DEGs in the TCGA dataset and 1069 DEGs in the GSE dataset were identified, including 87 overlapping genes between cancer and normal bladder groups. Hub genes in the tumor group were mainly enriched for cell proliferation, while hub genes in the normal group were related to the synthesis and secretion of neurotransmitters. Based on survival analysis, CDH19, RELN, PLP1, and TRIB3 were considerably associated with prognosis (P < 0.05). CDH19, RELN, PLP1, and TRIB3 may play important roles in the development of BC and are potential biomarkers in therapy and prognosis.
膀胱癌(BC)是对人类健康的重大威胁。为了确定治疗方案,有必要了解膀胱癌发生和发展的分子机制。从 TCGA 和 GEO 数据库中获取了公开的表达数据,以发现癌症和正常膀胱组织之间的差异表达基因(DEGs)。构建了加权共表达网络,并进行了基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析。分别评估了枢纽基因、免疫浸润和免疫治疗之间的关联。启动了在正常和肿瘤组中鉴定出的基因的蛋白质-蛋白质相互作用(PPI)网络。在 TCGA 数据集和 GSE 数据集中共鉴定出 3461 个 DEGs 和 1069 个 DEGs,其中包括癌症和正常膀胱组之间的 87 个重叠基因。肿瘤组中的枢纽基因主要富集于细胞增殖,而正常组中的枢纽基因与神经递质的合成和分泌有关。基于生存分析,CDH19、RELN、PLP1 和 TRIB3 与预后显著相关(P<0.05)。CDH19、RELN、PLP1 和 TRIB3 可能在膀胱癌的发生发展中发挥重要作用,是治疗和预后的潜在生物标志物。